



Animal and Cellular Models of Alzheimer's Disease

Guest Editors:

Dr. Juan A. García León

Dr. Kristine Freude

Dr. David Baglietto-Vargas

Deadline for manuscript
submissions:
closed (31 August 2023)

Message from the Guest Editors

Alzheimer's disease (AD) is a neurodegenerative condition with no cure. In the last three decades, important efforts have been made in the development and characterization of animal models of the disease, with the aim to translate the discoveries made toward the clinical setting.

This Special Issue is focused on manuscripts describing and/or characterizing new animal and cellular models for AD. Special attention will be given to those works employing humanized animal models as well as studies based on human pluripotent stem cell technologies, strategies that should govern AD research in the coming years.

This Special Issue is open to basic and clinical research or multidisciplinary approaches and will also cover original articles and reviews on the following topics:

- Characterization of new models relevant for AD;
- Studies performed employing new cellular and animal models focused on AD;
- Studies employing human pluripotent stem-cell-derived neuronal and glial cells for AD or other neurodegenerative conditions;
- Evaluation of candidate therapies;
- Modeling of Alzheimer's disease or other neurodegenerative conditions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI